ifosfamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives	1421	3778-73-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ifosfamide holoxan ifomide ifosfamid ifosfomide ifosphamide iphosphamide isoendoxan isofosfamide isophosphamide mitoxana naxamide	Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Molecular weight: 261.08 Formula: C7H15Cl2N2O2P CLOGP: 0.92 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.57 ALOGS: -1.24 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ifosfamide
holoxan
ifomide
ifosfamid
ifosfomide
ifosphamide
iphosphamide
isoendoxan
isofosfamide
isophosphamide
mitoxana
naxamide

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Molecular weight: 261.08
Formula: C7H15Cl2N2O2P
CLOGP: 0.92
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 41.57
ALOGS: -1.24
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	92 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
t_half (Half-life)	6.60 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	113.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	1.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.62 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1316.21	26.25	634	16127	117815	63354446
Encephalopathy	788.99	26.25	318	16443	38302	63433959
Neutropenia	648.55	26.25	460	16301	174545	63297716
Disease progression	559.47	26.25	367	16394	122391	63349870
Mucosal inflammation	491.23	26.25	242	16519	46686	63425575
Myelodysplastic syndrome	430.11	26.25	163	16598	16591	63455670
Ovarian failure	427.88	26.25	93	16668	1217	63471044
Bone marrow failure	420.62	26.25	188	16573	29102	63443159
Thrombocytopenia	355.28	26.25	304	16457	150853	63321408
Off label use	349.06	26.25	629	16132	673833	62798428

Showing 1 to 10 of 118 entries

Previous1 2 3 4 5…12Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1234.14	21.42	897	23112	135952	34796970
Disease progression	560.87	21.42	515	23494	107562	34825360
Neutropenia	487.03	21.42	567	23442	156211	34776711
Encephalopathy	447.81	21.42	287	23722	35032	34897890
Off label use	429.35	21.42	907	23102	418617	34514305
Myelodysplastic syndrome	338.70	21.42	193	23816	19015	34913907
Bone marrow failure	306.03	21.42	211	23798	29042	34903880
Acute myeloid leukaemia	265.41	21.42	162	23847	18108	34914814
Mucosal inflammation	260.06	21.42	214	23795	38408	34894514
Myelosuppression	257.50	21.42	162	23847	19103	34913819

Showing 1 to 10 of 147 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	2310.11	20.66	1389	35301	229610	79478088
Encephalopathy	1080.78	20.66	555	36135	66842	79640856
Neutropenia	1004.56	20.66	920	35770	286790	79420908
Disease progression	754.67	20.66	646	36044	183716	79523982
Bone marrow failure	669.32	20.66	368	36322	50739	79656959
Myelodysplastic syndrome	666.67	20.66	310	36380	29991	79677707
Off label use	646.22	20.66	1335	35355	905880	78801818
Mucosal inflammation	623.47	20.66	404	36286	75176	79632522
Thrombocytopenia	541.26	20.66	637	36053	264622	79443076
Acute myeloid leukaemia	540.11	20.66	270	36420	30615	79677083

Showing 1 to 10 of 248 entries

Previous1 2 3 4 5…25Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01AA06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000175558	Alkylating Drug
FDA MoA	N0000000236	Alkylating Activity
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018906	Antineoplastic Agents, Alkylating

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Testicular Germ Cell Tumor	indication
Ewing's sarcoma	off-label use	76909002	DOID:3369
Burkitt's lymphoma	off-label use	118617000
Small cell carcinoma of lung	off-label use	254632001	DOID:5409
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Soft or Connective Tissue Sarcoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Invasive Bladder Malignancy	off-label use

Showing 1 to 10 of 33 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.54	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
002642	NDDF
108757000	SNOMEDCT_US
2865	INN_ID
3690	PUBCHEM_CID
386904003	SNOMEDCT_US
4019476	VUID
4019476	VANDF
44391	MMSL
4867	MMSL
5657	RXNORM

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3991	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3991	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3993	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3993	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9531	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9531	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3427	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3429	INJECTION, SOLUTION	3 g	INTRAVENOUS	ANDA	26 sections

Showing 1 to 10 of 20 entries

Previous1 2Next